Insmed (INSM)
(Delayed Data from NSDQ)
$72.87 USD
-0.39 (-0.53%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $72.88 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Insmed, Inc. [INSM]
Reports for Purchase
Showing records 1 - 20 ( 124 total )
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Our Thoughts on Key Questions Ahead of Brensocatib NDA Filing; Reit. Buy and $90 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
KOL Thoughts on ASPEN Data Ahead of World Bronchiectasis Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Views on Clinical Progress in the Respiratory Field
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal ASPEN Trial Delivers For Brensocatib - Our Thoughts; Reit. Buy, Increasing PT to $70
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Positive Topline TPIP Safety and Tolerability Data - Optimistic on Near-Term Phase 3 ASPEN Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Expected 2Q24 Catalysts For Phase 3 ASPEN Trial and TPIP; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for INSM 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Dose Titration and Safety Insights Support TPIP - As ARISE Advances Arikayce With PRO Validation; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
ARISE Trial Delivers With Respiratory PRO - Setting Stage for ENCORE; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
2023 As the Year of Near-Term Catalysts, Arikayce Growth; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Turning New Page For Translational Pillar-Gene Therapy and Rare Disease Upside; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Arikayce Global Expansion and 2023 Catalysts For Broader Pipeline; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A